LOTTE Biologics and Ottimo Pharma Strengthen Their Strategic Partnership in Antibody Development
LOTTE Biologics, co-led by CEOs James Park and Yooyeol Shin, has recently announced the expansion of their collaboration with Ottimo Pharma, a pioneering biotechnology firm known for its innovative PD-1/VEGFR2 dual-paratopic antibodies. This collaboration marks a continued commitment to enhancing the strategic partnership initiated last year, reflecting the trust and confidence Ottimo Pharma places in LOTTE Biologics' operational capabilities and quality assurance.
The extended agreement goes beyond just manufacturing, focusing on advancing Ottimo Pharma's promising biparatopic antibody, OTP-01. Under this renewed collaboration, LOTTE Biologics’ team will support critical commercial process development and characterization activities at the Syracuse Bio Campus in New York. This engagement illustrates how both companies leverage their strengths to ensure the timely launch of revolutionary healthcare solutions.
The emphasis on a strong partnership underscores LOTTE Biologics' dedication to supporting its clients from the clinical development phase through to commercialization. As a pure-play Contract Development and Manufacturing Organization (CDMO), LOTTE Biologics provides comprehensive integrated services throughout the development and manufacturing continuum. Their dual-site strategy, which encompasses facilities in both Syracuse and Songdo, Korea, plays a crucial role in delivering consistent quality, operational flexibility, and reliability in supply.
James Park, CEO of LOTTE Biologics, remarked, "The trust we receive from our partners reinforces our view that a CDMO's role is not merely about delivery; it’s about comprehensively understanding and advancing our clients' molecules. Our commitment to our clients extends beyond just meeting operational needs—it's about ensuring speed, quality, and scalability as they move towards commercialization and meaningful patient impact."
Meanwhile, Spencer Fisk, Chief Technical and Quality Officer at Ottimo Pharma, emphasized the value of the collaboration, stating, "Our strong partnership with LOTTE Biologics has demonstrated exceptional execution speed and quality. Their rapid response capabilities have been critical as we initiated our Phase 1/2a study, and we are excited to deepen this relationship as we advance the development of OTP-01."
This partnership's expansion not only reinforces the mutual goals of both companies but also reflects a growing trend in the biotech industry where strategic collaborations are essential for bringing innovative therapies to market. LOTTE Biologics’ ability to deliver integrated solutions backed by operational excellence positions it as a key player in the global biopharmaceutical landscape.
As they continue to innovate, LOTTE Biologics and Ottimo Pharma collectively pave the way for breakthroughs that could potentially alter treatment paradigms, ultimately benefiting countless patients worldwide. This collaboration exemplifies how strategic foresight and operational synergy can catalyze significant advances in healthcare, paving the way for more effective treatments—an endeavor that resonates well in today’s rapidly evolving pharmaceutical landscape.
The extended agreement goes beyond just manufacturing, focusing on advancing Ottimo Pharma's promising biparatopic antibody, OTP-01. Under this renewed collaboration, LOTTE Biologics’ team will support critical commercial process development and characterization activities at the Syracuse Bio Campus in New York. This engagement illustrates how both companies leverage their strengths to ensure the timely launch of revolutionary healthcare solutions.
The emphasis on a strong partnership underscores LOTTE Biologics' dedication to supporting its clients from the clinical development phase through to commercialization. As a pure-play Contract Development and Manufacturing Organization (CDMO), LOTTE Biologics provides comprehensive integrated services throughout the development and manufacturing continuum. Their dual-site strategy, which encompasses facilities in both Syracuse and Songdo, Korea, plays a crucial role in delivering consistent quality, operational flexibility, and reliability in supply.
James Park, CEO of LOTTE Biologics, remarked, "The trust we receive from our partners reinforces our view that a CDMO's role is not merely about delivery; it’s about comprehensively understanding and advancing our clients' molecules. Our commitment to our clients extends beyond just meeting operational needs—it's about ensuring speed, quality, and scalability as they move towards commercialization and meaningful patient impact."
Meanwhile, Spencer Fisk, Chief Technical and Quality Officer at Ottimo Pharma, emphasized the value of the collaboration, stating, "Our strong partnership with LOTTE Biologics has demonstrated exceptional execution speed and quality. Their rapid response capabilities have been critical as we initiated our Phase 1/2a study, and we are excited to deepen this relationship as we advance the development of OTP-01."
This partnership's expansion not only reinforces the mutual goals of both companies but also reflects a growing trend in the biotech industry where strategic collaborations are essential for bringing innovative therapies to market. LOTTE Biologics’ ability to deliver integrated solutions backed by operational excellence positions it as a key player in the global biopharmaceutical landscape.
As they continue to innovate, LOTTE Biologics and Ottimo Pharma collectively pave the way for breakthroughs that could potentially alter treatment paradigms, ultimately benefiting countless patients worldwide. This collaboration exemplifies how strategic foresight and operational synergy can catalyze significant advances in healthcare, paving the way for more effective treatments—an endeavor that resonates well in today’s rapidly evolving pharmaceutical landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.